Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED) - Tabular View

Tracking Information
First Received Date ^ICMJE	June 28, 2002
Last Updated Date	May 31, 2006
Start Date ^ICMJE	June 2001
Primary Completion Date
Current Primary Outcome Measures ^ICMJE (submitted: June 23, 2005)	Adverse Events Laboratory Tests ECG
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	Complete list of historical versions of study NCT00040547 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE (submitted: June 23, 2005)	Physical Exam Pharmacokinetics Tumor Response
Original Secondary Outcome Measures ^ICMJE	Same as current

Descriptive Information
Brief Title ^ICMJE	Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)
Official Title ^ICMJE	Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors
Brief Summary	The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with intravenous docetaxel in cancer patients with advanced solid tumors.
Detailed Description
Study Phase	Phase I
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety Study
Condition ^ICMJE	Neoplasms
Intervention ^ICMJE	Drug: Farnesyl Protein Transferase Inhibitor
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	24
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion: Male or Female Measurable or evaluable disease No more than 2 prior chemotherapy regimens. Age greater than or equal to 18. Karnofsky Performance Status greater than or equal to 70%. Meets protocol requirements for specified laboratory values. No manifestations of a malabsorption syndrome. Written informed consent and cooperation of patient Appropriate use of effective contraception if of child-bearing potential. Exclusion: Acute or chronic leukemia or multiple myeloma. Evidence of 2 or more active malignancies, expect for in situ or adequately treated basal or squamous cell skin cancer.
Gender	Both
Ages	18 Years to 65 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE

Administrative Information
NCT ID ^ICMJE	NCT00040547
Responsible Party
Study ID Numbers ^ICMJE	P01964
Study Sponsor ^ICMJE	Schering-Plough
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Schering-Plough
Verification Date	May 2006
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP